CNR1 and neuropathy: Taken together, differential activation of CB1 and CB2 receptors by different cannabinoid agonists could help explain why we observe differences in the ability of the S426A/S430A mutation to alter anti-allodynic responses to select cannabinoid agonists in mice with cisplatin-evoked neuropathy.